8-K - Lipocine Inc. | StockGist

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Events. On January 20, 2026, the Company issued a press release announcing completion of enrollment and dosing in Phase 3 Trial of LPCN 1154 in postpartum

Other Event

9.01

Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed with this report: Exhibit No. Description 99.1 Press Release announcing Complet

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1